Home › Therapeutic areas › Oncology › Ovarian Cancer
Ovarian Cancer (17 companies)
Companies with an active program in Ovarian Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ANIX | Anixa Biosciences | Oncology | 2 | Phase 1 | $92.8M | 3 |
| AVBP | ArriVent BioPharma | Oncology | 1 | Phase 3 | $553M | 7 |
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $30.7M | 8 |
| CGEN | Compugen | Oncology | 2 | Phase 3 | $191M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $507M | 10 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | $279M | 13 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $96.1M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $2.65B | 15 |
| IMTX | Immatics | Oncology | 1 | Phase 3 | $958M | 8 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.44B | 12 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.03B | 9 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $92.2M | 7 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | $3.90B | 9 |
| VSTM | Verastem | Oncology | 1 | Approved | $934M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.59B | 28 |
| ZNTL | Zentalis Pharmaceuticals | Oncology | 1 | Phase 3 | $146M | 1 |
| ZYME | Zymeworks | OncologyRespiratory | 2 | Approved | $1.78B | 12 |
No companies match.